Skip to main content
. 2021 Nov 13;12(11):1080. doi: 10.1038/s41419-021-04381-5

Fig. 4. PRMT1-mediated meR342-EZH2 strengthens suppression of P16 and P21 transcriptional expression.

Fig. 4

A–D Western blotting detection of P16 and P21 expression after PRMT1 overexpression (A) or knockdown PRMT1 (B), or treated with PRMT1 (C) inhibitor AMI-1 (0.8 μM) or ectopic expression of Flag-EZH2-WT and Flag-EZH2-R342K (D) in MCF7 and MDA-MB-231 cells, respectively. E–H qRT-PCR detection of P16 and P21 expression after PRMT1 overexpression (E) or knockdown PRMT1 (F), or treated with PRMT1 (G) inhibitor AMI-1 (0.8 μM) or ectopic expression of Flag-EZH2-WT and Flag-EZH2-R342K (H) in MCF7 and MDA-MB-231 cells, respectively. I, J ChIP assays analysed EZH2 (I) and H3K27me3 (J) enrichment on P16 and P21 promoters in MDA-MB-231-shCtrl and MDA-MB-231-shPRMT1 cells. K, L Detection the enrichment of EZH2 (K) and H3K27me3 (L) on P16 and P21 promoters in MDA-MB-231-EZH2-WT and MDA-MB-231-EZH2-R342K cells by ChIP experiments. All the above experiments were replicated three times for statistical analyses (n = 3). Data are represented as mean ± SEM of three independent experiments and *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t-test).